ASX Junior at the Forefront of Cancer Research Could be Set for a Blockbuster Year

Mar 13, 2018

This biotech appears to have cracked one of the holy grails of cancer research: it’s currently in human clinical trials with not one, but two innovative drugs which ‘turn off the switch’ that would otherwise allow cancerous cells to grow via the important Akt and Ras pathways.

read article

Blockbuster Results from IMC’s NASH Liver Therapy Trials

Mar 08, 2018

Australian microbiome biopharmaceutical company, Immuron Limited (ASX:IMC | NASDAQ:IMRN) continues to progress its oral immunotherapies, to supply solutions for a growing unmet need.

read article

RSH on verge of commercialisation: on track to complete next-generation AirSonea

Feb 23, 2018

Respiri (ASX:RSH) is leading the way in new technologies to better manage asthma, a chronic disease affecting more than 330 million worldwide.

read article

CPH Gets Green Light to Distribute its Innovative CBD Based Nutraceutical Products in the UK

Jan 18, 2018

While much of the business world shut down over the Christmas-New Year’s break, diversified cannabis healthcare company Creso Pharma (ASX:CPH) has been busy on a number of fronts.

read article

CPH Seal Swiss Pharma Deal: Setting the Cornerstone for Global Commercialisation of cannaQIX

Dec 04, 2017

It has been a major month for Creso Pharma (ASX:CPH) as it continues to make potentially market moving announcements.

read article

Budding ASX Junior Pens Transformative Medical Cannabis Deals: Now Generating Revenue

Nov 23, 2017

MGC Pharmaceuticals (ASX:MXC) was the second company to originally emerge in the ASX cannabis corridor, and with a whip-smart team that’s put in serious hours in the industry-leading Israeli medicinal marijuana scene, this ASX junior is rapidly coming into its own.

read article

Could One ASX Junior Have All the Elements to Crack $121BN Natural Skincare Market?

Nov 15, 2017

This Australian-based developer of US FDA and Australia TGA approved natural and organic skin care products already has mainstream reach spanning over 15 countries, through its 100% natural and organic sunscreen Soleo Organics and is set to launch its organics sunscreen range into the US$10BN global suncare market.

read article

CPH Launches First Animal Product in Partnership with Global Animal Health Giant

Nov 14, 2017

Creso Pharma (ASX: CPH) has hit a major milestone with the launch of its first animal health product in Switzerland and Lichtenstein.

read article

IMU Picks up the Pace in Cancer Drug Treatment Development

Aug 09, 2017

It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.

read article

CPH to Acquire Canadian Cannabis Grower and Strengthen Position in Multi-Billion Dollar Market

Jul 27, 2017

Creso Pharma (ASX:CPH) is now in the box seat to acquire 100% of Canadian-based Mernova Medicinal Inc., an acquisition that would position CPH as a Canadian producer of legal cannabis.

read article

CPH Signs Exclusive Cannapharm deal: On Track for 2017 Product Release

Jun 14, 2017

News of $100 million IPOs, alongside an avalanche of parallel legislative changes around the world, builds a strong case for the burgeoning medicinal marijuana industry. With so many medicinal cannabis stocks fighting for market share and threatening to steal the limelight, a company such as Creso Pharma Ltd (ASX: CPH) needs to do all it can to stay current and competitive.

read article

IMC Hits Key Milestones Ahead of Imminent NASDAQ Listing

May 17, 2017

Immuron Limited (ASX: IMC) is working in the realm of oral immunotherapies, targeting inflammatory-mediated and infectious diseases and is uniquely positioned to address large unmet needs.

read article

CPH Deliver Australia’s First Medicinal Cannabis Shipment Under New Legislation

May 02, 2017

Creso Pharma (ASX: CPH) has made a shipment of medicinal cannabis into Australia – the first import into the country under new government legislation. Under an agreement between CPH and its Australian partner, Health House International Pty Ltd, the pair will distribute a range of cannabis oil products across Australian pharmacies, in compliance with Federal and State legislation.

read article

Beating Cancer via Early Detection: ASX Stock Targeting Multiple Billion Dollar Markets

Apr 04, 2017

If you are going to beat cancer, your best bet is to catch it early. Of course, that’s easier said than done. By the time the symptoms of many cancers are apparent, a patient is often already in late stages of the disease. This is particularly true for lung cancer.

read article

ASX Stock to Launch on NASDAQ with Gut Busting Immunotherapy Products

Mar 24, 2017

Today’s $30 million capped ASX listed biotech player, which is in the process of listing on the NASDAQ, has thus far flown right under the radar of Australia’s biotech landscape. This scenario is likely to change, however, as this cutting edge company has chosen to take aim at the oral immunotherapy sector, with antibody products […]

read article

Medical Marijuana Stock CPH Plants First Seeds in $800M Brazilian Market

Mar 22, 2017

There is no doubt about it – medical marijuana stocks are lighting up the ASX right now, as the mainstream media and investment community at large is finally starting to pick up on what we have been saying for over 12 months now.

read article

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?

Mar 16, 2017

One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.

read article

Aussie Medical Cannabis Market Opens Up: CPH Takes Early Mover Advantage

Mar 01, 2017

Creso Pharma (ASX:CPH) is one company set to benefit from the Australian Federal Government’s move this month to improve access to medical cannabis and grant import/export licenses.

read article
Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.